The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9687548 B1

PDF
Full Text
Expired
Date of Patent:
Jun. 27, 2017

Filed:

Mar. 14, 2013
Applicants:

Dana-farber Cancer Institute, Inc., Boston, MA (US);

The General Hospital Corporation, Boston, MA (US);

Inventors:

Xin Lu, Houston, TX (US);

Sarit S. Agasti, Cambridge, MA (US);

Ronald A. DePinho, Houston, TX (US);

Ralph Weissleder, Peabody, MA (US);

Assignees:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 41/00 (2006.01); A61K 31/137 (2006.01); A61K 31/155 (2006.01); A61K 31/40 (2006.01); A61K 31/4453 (2006.01); A61K 31/495 (2006.01); A61K 31/5375 (2006.01); A61K 35/12 (2015.01); C12N 9/00 (2006.01); A61K 35/30 (2015.01); A61K 35/32 (2015.01); A61K 35/34 (2015.01); A61K 35/35 (2015.01); A61K 35/36 (2015.01); A61K 35/44 (2015.01); A61K 45/06 (2006.01); A61K 47/48 (2006.01); A61N 5/06 (2006.01); C07C 279/08 (2006.01); C07C 217/18 (2006.01); C07D 295/088 (2006.01);
U.S. Cl.
CPC ...
A61K 41/0057 (2013.01); A61K 31/137 (2013.01); A61K 31/155 (2013.01); A61K 31/40 (2013.01); A61K 31/4453 (2013.01); A61K 31/495 (2013.01); A61K 31/5375 (2013.01); A61K 35/30 (2013.01); A61K 35/32 (2013.01); A61K 35/34 (2013.01); A61K 35/35 (2013.01); A61K 35/36 (2013.01); A61K 35/44 (2013.01); A61K 45/06 (2013.01); A61K 47/48023 (2013.01); A61N 5/062 (2013.01); C07C 217/18 (2013.01); C07C 279/08 (2013.01); C07D 295/088 (2013.01); C12N 9/00 (2013.01); C07C 2101/14 (2013.01); C07K 2319/09 (2013.01);
Abstract

Provided herein are compositions containing photoactivatable caged tamoxifen and tamoxifen derivative molecules. Also provided are kits containing one of these compositions and a light source. Also provided are methods of optically inducing nuclear translocation of a fusion protein containing a mammalian estrogen receptor ligand binding domain in a eukaryotic cell and methods of optically inducing recombination in a eukaryotic cell that include contacting a eukaryotic cell with at least one of these compositions. Also provided are methods of treating breast cancer in a subject that include administering a photoactivatable caged tamoxifen or tamoxifen derivative molecule to a subject having breast cancer.


Find Patent Forward Citations

Loading…